|
|
Article: Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome.
- Article from:
- PR Newswire
- Article date:
- November 28, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Conference Call and Webcast at 8:30 a.m. ET Today -
BRANFORD, Conn., Nov. 28 /PRNewswire-FirstCall/ -- Neurogen Corporation today announced it has acquired from Wyeth Pharmaceuticals, a division of Wyeth , worldwide development and commercialization rights to Aplindore, a small molecule partial agonist for the D2 dopamine receptor. Neurogen expects to commence Phase II trials in Parkinson's disease and restless legs syndrome (RLS) with Aplindore during 2007, following the manufacture of clinical supplies.
Aplindore was initially developed by Wyeth for schizophrenia and has been studied in six Phase I and Phase II clinical trials involving over 100 ...